ABP 501 regulatory update

FDA accepted for review a BLA from Amgen for ABP 501, a biosimilar of autoimmune drug Humira adalimumab from AbbVie Inc. (NYSE:ABBV, Chicago, Ill.). Its action date under the Biosimilar User Fee Act...